Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of December 2025, specifically detailing a share repurchase executed on December 17, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Transaction Date: December 17, 2025
- Shares Purchased: 235,000 ordinary shares
- Price Range: 1,824.00p (Low) to 1,850.00p (High)
- Volume-Weighted Average Price (VWAP): 1,841.56p
- Broker: BNP Paribas SA
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
- Treasury Share Status: Purchased shares are held as Treasury shares.
Material Changes and Cumulative Activity
This transaction is part of an existing buyback programme initiated via a non-discretionary agreement announced on September 30, 2025.
- Cumulative Purchases: Since September 30, 2025, GSK has purchased a total of 14,086,733 ordinary shares.
- Total Treasury Shares: Following this purchase, the company holds 239,551,577 ordinary shares in treasury.
- Shares in Issue: 4,075,889,506 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.88% of the total voting rights.
Guidance, Outlook, and Risks
The filing does not contain new financial guidance, management commentary on operational performance, or specific risk factors beyond standard disclosures.
- Forward-Looking Statements: The document includes a cautionary statement noting that any forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
- Reference to Risks: Investors are directed to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q3 Results for 2025 for a detailed description of risks.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,075,889,506) to calculate accurate ownership percentages under Disclosure Guidance and Transparency Rules (DTR).
- Confirm the 5.88% voting rights held in treasury, as these shares do not carry voting rights.
- Note that the buyback is executed via a non-discretionary agreement with BNP Paribas SA, meaning the company has limited control over the specific timing and price of individual trades within the programme.
- Review the cumulative buyback volume (14,086,733 shares since late September) to assess the remaining capacity of the current programme.